OX40 Receptor Binding Molecules for T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments lack effective methods to enhance anti-tumor T cell function, particularly in enhancing CD4+ helper T cell activity and providing survival signals for memory and effector T cells, which are crucial for an effective immune response against tumors.
Innovation Solution
Development of isolated binding molecules, such as OX40R antibodies and their antigen-binding fragments, that specifically bind to the OX40 receptor with high affinity, acting as agonists to stimulate or activate the OX40 receptor, thereby enhancing immune responses and inhibiting tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments are used, then tumor growth is addressed through traditional methods, but anti-tumor T cell function is not effectively enhanced
Solution Approach 1:
The patent introduces OX40R binding molecules as intermediary agents that mediate between the immune system and tumor cells. These molecules specifically bind to OX40 receptors on T cells, delivering co-stimulatory signals that enhance T cell activation, proliferation, and survival without requiring direct tumor-cell contact, thereby reliably enhancing anti-tumor T cell function
Solution Approach 2:
The patent modifies the immunological parameters of T cell responses by using OX40R binding molecules to alter key parameters including T cell activation thresholds, proliferation rates, and survival signals. This changes the functional state of T cells from a conventional treatment approach to an immunologically optimized state, effectively enhancing anti-tumor activity
2Reliability
If OX40R binding molecules are used to enhance immune response, then T cell activity is improved, but the complexity of the therapeutic approach increases
Solution Approach 1:
The patent extracts the specific OX40R binding function from complex immune system interactions and isolates it into discrete, purified antibody molecules. This extraction allows the therapeutic agent to focus on a single, well-defined mechanism (OX40R binding) rather than requiring complex combinations of multiple immunomodulatory agents, thereby improving T cell activity while managing therapeutic complexity
Solution Approach 2:
The OX40R binding molecules exhibit multi-functionality by simultaneously providing co-stimulatory signals for T cell activation, promoting T cell survival through anti-apoptotic effects, and enhancing cytokine production. This single agent performs multiple immunomodulatory functions that would otherwise require separate therapeutic interventions, improving T cell activity without proportionally increasing therapeutic complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The binding molecules effectively enhance anti-tumor immune responses by stimulating OX40R, leading to increased IL-2 production, improved T cell activity, and inhibition of tumor growth, providing a therapeutic approach for cancer treatment.
Implementation Method 1
isolated binding molecules that bind to the human OX40R, including OX40R antibodies, antigen-binding fragments of the OX40R antibodies
Implementation Method 2
have agonist activity on the human OX40R
Data Source
AI summary
The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.